Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 4Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Hodgkin Disease 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Disease Progression 1

Interventions

Cyclophosphamide 24Mycophenolic Acid 15fludarabine phosphate 14fludarabine 13Whole-Body Irradiation 13Tacrolimus 12Rituximab 12Melphalan 12Filgrastim 11Cyclosporine 11Busulfan 11Radiotherapy 10Peripheral Blood Stem Cell Transplantation 10Antilymphocyte Serum 10Methotrexate 9Doxorubicin 9Gemcitabine 8Etoposide 8Brentuximab Vedotin 8Sirolimus 7pembrolizumab 6Vinblastine 6Nivolumab 6Methylprednisolone 6Granulocyte Colony-Stimulating Factor 6Alemtuzumab 6Dacarbazine 5Cytarabine 5Cord Blood Stem Cell Transplantation 5Carmustine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hodgkin Disease × umbralisib × Clear all
NCT03776864 2023-05-03

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

University of Washington

Phase 2 Terminated
6 enrolled 8 charts
Lymphoid

Hodgkin Disease

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Columbia University

Phase 1/2 Terminated
14 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡